Friday, May 20, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Inflammatix Wins BARDA Backing for Diagnostic to Rapidly Distinguish Bacterial from Viral Infections

by Global Biodefense Staff
November 25, 2019
Klebsiella pneumoniae

A human neutrophil interacting with Klebsiella pneumoniae (pink), a multidrug–resistant bacterium that causes severe hospital infections. Credit: NIAID

A novel diagnostics technology that reads gene expression patterns in the immune system to distinguish bacterial infections from viral infections and determines the severity within minutes will receive advanced development support from the U.S. Department of Health and Human Services (HHS). The technology is being designed for use in outpatient and inpatient healthcare settings.

The Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), will support the advanced development of the new testing technology, known as host-response testing, under a 14-month, $6 million contract with Inflammatix Inc., of Burlingame, California.

This agreement can be extended to provide BARDA’s financial and technical support, up to a total of $64.9 million through 2027, for the company to complete the additional work needed to apply for U.S. Food and Drug Administration (FDA) clearance of the tests.

“Rapid diagnostics are a cornerstone of our strategy to protect Americans from many bacterial and viral infections; earlier diagnosis can empower patients to take action to reduce disease transmission,” said BARDA Director Rick Bright, Ph.D. “Antimicrobial resistance is a growing threat to public health and the health security of the United States, and diagnostics that can provide rapid results to patients and doctors will support stewardship of antibiotics and save lives.”

The first Inflammatix test, called HostDx Fever, is intended to help distinguish bacterial from viral infections in outpatient ambulatory settings; the second test, called HostDx Sepsis, is intended for inpatient hospital settings and also may determine whether a patient is likely to develop sepsis. The third test, HostDx FeverFlu, is intended for use in either setting during influenza season and combines rapid flu testing with host-response data.

“We are thrilled to receive this funding from BARDA, which will enable us to advance our HostDx Fever test into the clinic where it will help physicians quickly diagnose infections so they can get the right treatments to the right patients. This ability is key to combatting antibiotic resistance, which is one of the most pressing public health challenges of our time,” said Tim Sweeney, M.D., Ph.D., cofounder and chief executive officer of Inflammatix. “Through this public-private sector partnership, we will move precision medicine to the point of care, where it can have an immediate impact on patient outcomes.”

Tags: BARDAEditor PickPOC Diagnostics

Related Posts

NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools
Biodetection

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022
Rapid COVID-19 PCR Test Developed at Northwestern Receives FDA Emergency Use Authorization
Biodetection

Rapid COVID-19 PCR Test Developed at Northwestern Receives FDA Emergency Use Authorization

March 19, 2022
There’s No Such Thing as Just-in-Time Healthcare and Public Health Preparedness
Industry News

Appili Awarded $10M in New Biodefense Funding for Tularemia Vaccine Candidate

March 3, 2022
Load More

Latest News

NIH to Further Invest in Point-of-Care Technologies Research Network

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC